Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 113

1.

Clinical optimization of antigen specific modulation of type 1 diabetes with the plasmid DNA platform.

Gottlieb P, Utz PJ, Robinson W, Steinman L.

Clin Immunol. 2013 Dec;149(3):297-306. doi: 10.1016/j.clim.2013.08.010. Epub 2013 Sep 1. Review.

2.

Plasmid-encoded proinsulin preserves C-peptide while specifically reducing proinsulin-specific CD8⁺ T cells in type 1 diabetes.

Roep BO, Solvason N, Gottlieb PA, Abreu JRF, Harrison LC, Eisenbarth GS, Yu L, Leviten M, Hagopian WA, Buse JB, von Herrath M, Quan J, King RS, Robinson WH, Utz PJ, Garren H; BHT-3021 Investigators, Steinman L.

Sci Transl Med. 2013 Jun 26;5(191):191ra82. doi: 10.1126/scitranslmed.3006103.

3.

Islet-Derived CD4 T Cells Targeting Proinsulin in Human Autoimmune Diabetes.

Michels AW, Landry LG, McDaniel KA, Yu L, Campbell-Thompson M, Kwok WW, Jones KL, Gottlieb PA, Kappler JW, Tang Q, Roep BO, Atkinson MA, Mathews CE, Nakayama M.

Diabetes. 2017 Mar;66(3):722-734. doi: 10.2337/db16-1025. Epub 2016 Dec 5.

4.

Responses against islet antigens in NOD mice are prevented by tolerance to proinsulin but not IGRP.

Krishnamurthy B, Dudek NL, McKenzie MD, Purcell AW, Brooks AG, Gellert S, Colman PG, Harrison LC, Lew AM, Thomas HE, Kay TW.

J Clin Invest. 2006 Dec;116(12):3258-65.

5.

Intranasal vaccination with proinsulin DNA induces regulatory CD4+ T cells that prevent experimental autoimmune diabetes.

Every AL, Kramer DR, Mannering SI, Lew AM, Harrison LC.

J Immunol. 2006 Apr 15;176(8):4608-15.

6.

Identification of Candidate Tolerogenic CD8(+) T Cell Epitopes for Therapy of Type 1 Diabetes in the NOD Mouse Model.

Yu C, Burns JC, Robinson WH, Utz PJ, Ho PP, Steinman L, Frey AB.

J Diabetes Res. 2016;2016:9083103. doi: 10.1155/2016/9083103. Epub 2016 Mar 16.

7.

IGRP and insulin vaccination induce CD8+ T cell-mediated autoimmune diabetes in the RIP-CD80GP mouse.

Fuchs YF, Adler K, Lindner A, Karasinsky A, Wilhelm C, Weigelt M, Balke H, Förtsch K, Mortler-Hildebrandt LF, Harlan DM, Pechhold K, Ziegler AG, Bonifacio E.

Clin Exp Immunol. 2014 May;176(2):199-206. doi: 10.1111/cei.12263.

8.

Analysis of antigen specific T cells in diabetes - Lessons from pre-clinical studies and early clinical trials.

Krishnamurthy B, Selck C, Chee J, Jhala G, Kay TW.

J Autoimmun. 2016 Jul;71:35-43. doi: 10.1016/j.jaut.2016.03.018. Epub 2016 Apr 12. Review.

PMID:
27083395
9.

Similar peptides from two beta cell autoantigens, proinsulin and glutamic acid decarboxylase, stimulate T cells of individuals at risk for insulin-dependent diabetes.

Rudy G, Stone N, Harrison LC, Colman PG, McNair P, Brusic V, French MB, Honeyman MC, Tait B, Lew AM.

Mol Med. 1995 Sep;1(6):625-33.

10.

Transfer of hematopoietic stem cells encoding autoantigen prevents autoimmune diabetes.

Steptoe RJ, Ritchie JM, Harrison LC.

J Clin Invest. 2003 May;111(9):1357-63.

11.

Proinsulin peptide immunotherapy in type 1 diabetes: report of a first-in-man Phase I safety study.

Thrower SL, James L, Hall W, Green KM, Arif S, Allen JS, Van-Krinks C, Lozanoska-Ochser B, Marquesini L, Brown S, Wong FS, Dayan CM, Peakman M.

Clin Exp Immunol. 2009 Feb;155(2):156-65. doi: 10.1111/j.1365-2249.2008.03814.x. Epub 2008 Nov 20.

12.

Transient B-cell depletion with anti-CD20 in combination with proinsulin DNA vaccine or oral insulin: immunologic effects and efficacy in NOD mice.

Sarikonda G, Sachithanantham S, Manenkova Y, Kupfer T, Posgai A, Wasserfall C, Bernstein P, Straub L, Pagni PP, Schneider D, Calvo TR, Coulombe M, Herold K, Gill RG, Atkinson M, Nepom G, Ehlers M, Staeva T, Garren H, Steinman L, Chan AC, von Herrath M.

PLoS One. 2013;8(2):e54712. doi: 10.1371/journal.pone.0054712. Epub 2013 Feb 6.

13.

Characterization of preparations of GAD65, proinsulin, and the islet tyrosine phosphatase IA-2 for use in detection of autoreactive T-cells in type 1 diabetes: report of phase II of the Second International Immunology of Diabetes Society Workshop for Standardization of T-cell assays in type 1 diabetes.

Peakman M, Tree TI, Endl J, van Endert P, Atkinson MA, Roep BO; Second International Immunology of Diabetes Society Workshop for Standardization ot T-cell Assays in Type 1 Diabetes.

Diabetes. 2001 Aug;50(8):1749-54.

14.

Proinsulin-specific, HLA-DQ8, and HLA-DQ8-transdimer-restricted CD4+ T cells infiltrate islets in type 1 diabetes.

Pathiraja V, Kuehlich JP, Campbell PD, Krishnamurthy B, Loudovaris T, Coates PT, Brodnicki TC, O'Connell PJ, Kedzierska K, Rodda C, Bergman P, Hill E, Purcell AW, Dudek NL, Thomas HE, Kay TW, Mannering SI.

Diabetes. 2015 Jan;64(1):172-82. doi: 10.2337/db14-0858. Epub 2014 Aug 25.

15.

CD8 T-cell reactivity to islet antigens is unique to type 1 while CD4 T-cell reactivity exists in both type 1 and type 2 diabetes.

Sarikonda G, Pettus J, Phatak S, Sachithanantham S, Miller JF, Wesley JD, Cadag E, Chae J, Ganesan L, Mallios R, Edelman S, Peters B, von Herrath M.

J Autoimmun. 2014 May;50:77-82. doi: 10.1016/j.jaut.2013.12.003. Epub 2013 Dec 30.

PMID:
24387802
16.

Predominantly recognized proinsulin T helper cell epitopes in individuals with and without islet cell autoimmunity.

Durinovic-Belló I, Boehm BO, Ziegler AG.

J Autoimmun. 2002 Feb;18(1):55-66.

PMID:
11869047
17.

The sentinel role of CD8 T cells in regulating CD4 T cell responses to proinsulin in beta-islet cell autoimmunity.

Batarelo V, Durinovic-Belló I.

Ann N Y Acad Sci. 2008 Dec;1150:270-2. doi: 10.1196/annals.1447.047.

PMID:
19120311
18.

Insulin as a primary autoantigen for type 1A diabetes.

Jasinski JM, Eisenbarth GS.

Clin Dev Immunol. 2005 Sep;12(3):181-6. Review.

19.

Evidence that a peptide spanning the B-C junction of proinsulin is an early Autoantigen epitope in the pathogenesis of type 1 diabetes.

Chen W, Bergerot I, Elliott JF, Harrison LC, Abiru N, Eisenbarth GS, Delovitch TL.

J Immunol. 2001 Nov 1;167(9):4926-35.

20.

Experimental autoimmune insulitis. Induction by T lymphocytes specific for a peptide of proinsulin.

Griffin AC, Zhao W, Wegmann KW, Hickley WF.

Am J Pathol. 1995 Sep;147(3):845-57.

Supplemental Content

Support Center